Fludarabine Modulates Immune Response and Extends In Vivo Survival of Adoptively Transferred CD8 T Cells in Patients with Metastatic Melanoma

Herschel Wallen, John A. Thompson, J. Zachary Reilly et al. · 2009

Read Fludarabine Modulates Immune Response and Extends In Vivo Survival of Adoptively Transferred CD8 T Cells in Patients with Metastatic Melanoma by Herschel Wallen, John A. Thompson, J. Zachary Reilly et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0004749.txt.

Description

Herschel Wallen and colleagues found that a chemo drug helps transferred T cells live longer in melanoma patients, in PLOS ONE in 2009. The therapy grows tumor specific killer T cells outside the body and returns them to the patient. How long those cells persist is linked to how well the treatment works against the tumor.

The team tested fludarabine, a drug that can shape immune response. It boosted response and stretched the survival of transferred cells in patients with spread melanoma. Longer lived cells may give the immune attack more time to shrink tumors. The approach needs care, since the drug also lowers immunity.

Catalog record

CREATORHerschel Wallen, John A. Thompson, J. Zachary Reilly et al.
YEAR2009
COLLECTIONPAPERS
FORMATTXT
FILE SIZE43 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0004749

Browse the full library · About the Tower of Babel